GSK (GSK) said Monday that the European Medicines Agency has agreed to review its prefilled syringe version of Shingrix, a vaccine for the prevention of shingles.
The company said the prefilled syringes do away with the need to mix separate vials before jabs.
The regulatory review follows the Jan. 8 US Food and Drug Administration acceptance of the prefilled syringes, the company said.
GSK said it is also considering submitting the product for review in other markets.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。